top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Michael A. McManus, Jr. net worth and biography

Michael McManus, Jr. Biography and Net Worth

Director of Novavax

Mr. McManus joined the Novavax board of directors in 1998. He has served as president, chief executive officer, and director at Misonix, Inc., a medical, scientific, and industrial provider of ultrasonic and air pollution systems, since 1998. Previously, he was president and chief executive officer at New York Bancorp Inc. from 1991 to 1998. From 1990 through November 1991, Mr. McManus was president and chief executive officer at Jamcor Pharmaceuticals Inc. Previously, Mr. McManus served as an assistant to the President of the United States from 1982 to 1985 and held positions with Pfizer Inc. and Revlon Group. Mr. McManus received a BA in economics from the University of Notre Dame and a JD from the Georgetown University Law Center. He served in the US Army Infantry from 1968 through 1970. He is also a recipient of the Ellis Island Medal of Honor.

What is Michael A. McManus, Jr.'s net worth?: The estimated net worth of Michael A. McManus, Jr. is at least $37,146.65 as of March 19th, 2021. Mr. McManus, Jr. owns 8,951 shares of Novavax stock worth more than $37,147 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. McManus, Jr. may own. Learn More about Michael A. McManus, Jr.'s net worth.
How do I contact Michael A. McManus, Jr.?: The corporate mailing address for Mr. McManus, Jr. and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on Michael A. McManus, Jr.'s contact information.
Has Michael A. McManus, Jr. been buying or selling shares of Novavax?: Michael A. McManus, Jr. has not been actively trading shares of Novavax over the course of the past ninety days. Most recently, Michael A. Mcmanus, Jr. sold 4,000 shares of the business's stock in a transaction on Friday, March 19th. The shares were sold at an average price of $220.78, for a transaction totalling $883,120.00. Following the completion of the sale, the director now directly owns 8,951 shares of the company's stock, valued at $1,976,201.78. Learn More on Michael A. McManus, Jr.'s trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (EVP), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.

Michael A. McManus, Jr. Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2021	Sell	4,000	$220.78	$883,120.00	8,951
8/18/2020	Sell	8,000	$146.00	$1,168,000.00	13,951
11/18/2019	Sell	3,929	$3.82	$15,008.78	9,951
5/12/2017	Buy	20,000	$0.97	$19,400.00	277,590
5/11/2017	Buy	10,000	$0.84	$8,400.00	257,590
9/21/2016	Buy	30,000	$1.61	$48,300.00	247,590

Michael A. McManus, Jr. Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $4.15

$4.10

$4.26

50 Day Range

MA: $4.71

$3.89

$6.02

2 Week Range

Now: $4.15

$3.53

$11.36

Volume

2,991,386 shs

Average Volume

3,507,988 shs

Market Capitalization

$580.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59